title: [Efficacy of chemotherapy with carboplatin-paclitaxel plus bevacizumab for previously treated patients with advanced non-small cell carcinoma].
abstract: BACKGROUND
  There have been few reports on the efficacy or safety of combination therapy with carboplatin-paclitaxel plus bevacizumab(TC+Bev)in previously treated patients with non-small cell lung carcinoma(NSCLC).
  
  
  OBJECTIVE
  The objective of this study was to assess the efficacy and safety of TC+Bev as second-line therapy and beyond for previously treated NSCLC patients.
  
  
  METHODS
  A total of 17 patients previously treated with NSCLC at the Kitasato University Hospital between April 2010 and February 2012 were enrolled in this retrospective study. On day 1 all patients received a 200mg/m2 dose of paclitaxel by intravenous infusion over a 3-h period, followed by infusion of carboplatin at a dose corresponding to an AUC of 6.0 min mg/mL, and then by Bev at a dose of 15mg/m2. The treatment course was repeated every three or four weeks. Patients continued to receive Bev monotherapy every 3 weeks thereafter until evidence of disease progression or unacceptable toxicity developed.
  
  
  RESULTS
  Median age: 60 years old(range 39-74 years old); gender: male/female, 6/11; PS 0-1/≥2, 17/0; clinical stage:III B/IV postoperative recurrence, 0/16/1; EGFR mutation status: positive/negative/unknown, 7/9/1; histological type: adenocarcinoma in all patients; median number of prior regimens: 3. 4(1-6); median number of cycles(induction phase): 3(1-6). The objective response rate and disease control rate were 17. 6% and 70. 6%, respectively, and the median progression-free survival time was 4. 7 months. There were no treatment-related deaths, and the toxicities of the treatment regimen were acceptable.
  
  
  CONCLUSIONS
  TC+Bev therapy exhibits activity in previously treated NSCLC patients and has acceptable toxicity. Further study is warranted to confirm our results.
authors.affiliation: Dept. of Respiratory Medicine, Kitasato University School of Medicine, Japan.
authors.forename: Sachiyo
authors.initials: S
authors.lastname: Maki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Igawa
authors.forename: Sakiko
authors.initials: S
authors.lastname: Otani
authors.forename: Yujiro
authors.initials: Y
authors.lastname: Nagashima
authors.forename: Michiko
authors.initials: M
authors.lastname: Kimura
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Hiyoshi
authors.forename: Mikiko
authors.initials: M
authors.lastname: Ishihara
authors.forename: Masashi
authors.initials: M
authors.lastname: Kasajima
authors.forename: Ken
authors.initials: K
authors.lastname: Katono
authors.forename: Akira
authors.initials: A
authors.lastname: Takakura
authors.forename: Masaru
authors.initials: M
authors.lastname: Kubota
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Masuda
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D016879:Salvage Therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel